Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regarding the Publication

Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regarding the Publication of Major Shareholdings (the "Transparency Law")

ID: 257812

REGULATED INFORMATION


(firmenpresse) - GHENT, BELGIUM -- (Marketwired) -- 05/08/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from KBC Asset Management NV.

KBC Asset Management NV notified that they have dropped below the 3% threshold.

Full versions of all transparency notifications are available on the website of Ablynx, under the section Investors.

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and five Nanobodies at clinical development stage. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck Serono, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium.
More information can be found on .

press release in pdf format:



Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193
+32 (0)473 39 50 68
e:

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:
Follow us on Twitter (at)AblynxABLX

Mary-Jane Elliott
Amber Bielecka
Claire Dickinson
t: +44 207 920 2330
e:




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  The Medicines Company to Participate in Bank of America Merrill Lynch 2013 Health Care Conference Trimel Pharmaceuticals Corporation Announces First Quarter 2013 Financial Results
Bereitgestellt von Benutzer: Marketwired
Datum: 08.05.2013 - 16:52 Uhr
Sprache: Deutsch
News-ID 257812
Anzahl Zeichen: 0

contact information:
Town:

GHENT, BELGIUM



Kategorie:

Healthcare



Diese Pressemitteilung wurde bisher 311 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regarding the Publication of Major Shareholdings (the "Transparency Law")"
steht unter der journalistisch-redaktionellen Verantwortung von

Ablynx (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Ablynx Announces Half-Year Results for 2013 ...

GHENT, BELGIUM -- (Marketwired) -- 08/21/13 -- (EURONEXT BRUSSELS: ABLX) today announced its results for the six-month period ending 30 June 2013, which have been prepared in accordance with the IAS 34 "Interim Financial Reporting" as adop ...

Ablynx Announces Warrant Exercise ...

GHENT, BELGIUM -- (Marketwired) -- 07/23/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 273,913 common shares have been issued by the ...

Alle Meldungen von Ablynx



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z